Portacci Andrea, Iorillo Ilaria, Maselli Leonardo, Amendolara Monica, Quaranta Vitaliano Nicola, Dragonieri Silvano, Carpagnano Giovanna Elisiana
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70121 Bari, Italy.
Respiratory Disease Department, "Di Venere" Hospital, 70121 Bari, Italy.
Curr Issues Mol Biol. 2024 May 3;46(5):4271-4285. doi: 10.3390/cimb46050260.
Galectins are a group of β-galactoside-binding proteins with several roles in immune response, cellular adhesion, and inflammation development. Current evidence suggest that these proteins could play a crucial role in many respiratory diseases such as pulmonary fibrosis, lung cancer, and respiratory infections. From this standpoint, an increasing body of evidence have recognized galectins as potential biomarkers involved in several aspects of asthma pathophysiology. Among them, galectin-3 (Gal-3), galectin-9 (Gal-9), and galectin-10 (Gal-10) are the most extensively studied in human and animal asthma models. These galectins can affect T helper 2 (Th2) and non-Th2 inflammation, mucus production, airway responsiveness, and bronchial remodeling. Nevertheless, while higher Gal-3 and Gal-9 concentrations are associated with a stronger degree of Th-2 phlogosis, Gal-10, which forms Charcot-Leyden Crystals (CLCs), correlates with sputum eosinophilic count, interleukin-5 (IL-5) production, and immunoglobulin E (IgE) secretion. Finally, several galectins have shown potential in clinical response monitoring after inhaled corticosteroids (ICS) and biologic therapies, confirming their potential role as reliable biomarkers in patients with asthma.
半乳糖凝集素是一类β-半乳糖苷结合蛋白,在免疫反应、细胞黏附和炎症发展中发挥多种作用。目前的证据表明,这些蛋白在许多呼吸系统疾病中可能起关键作用,如肺纤维化、肺癌和呼吸道感染。从这个角度来看,越来越多的证据已将半乳糖凝集素视为参与哮喘病理生理学多个方面的潜在生物标志物。其中,半乳糖凝集素-3(Gal-3)、半乳糖凝集素-9(Gal-9)和半乳糖凝集素-10(Gal-10)在人类和动物哮喘模型中研究最为广泛。这些半乳糖凝集素可影响辅助性T细胞2(Th2)和非Th2炎症、黏液产生、气道反应性和支气管重塑。然而,虽然较高的Gal-3和Gal-9浓度与较强程度的Th2炎症相关,但形成夏科-莱登结晶(CLCs)的Gal-10与痰液嗜酸性粒细胞计数、白细胞介素-5(IL-5)产生和免疫球蛋白E(IgE)分泌相关。最后,几种半乳糖凝集素在吸入性糖皮质激素(ICS)和生物治疗后的临床反应监测中显示出潜力,证实了它们在哮喘患者中作为可靠生物标志物的潜在作用。